CD47 and osteosarcoma: This M1-TAM activation lead to increased tumor uptake of non-targeted nanoparticles and this effect could be imaged with MRI: Ferumoxytol-MRI was used to monitor response to anti-CD47 mAb therapy in mouse models of glioblastomas (Figure 5) and osteosarcomas 134, as noted by an increasingly negative (dark) nanoparticle enhancement of the tumor tissue compared to pre-treatment scans 134.